Poly MVA – Alternative Treatment for Multiple Cancers
Overview
Poly-MVA is an effective, safe and very intriguing way of targeting cancer. It approaches cancer from a very different perspective than most other alternative treatment plans. Dr. Garnett’s almost 50 years of testing has yielded organic-metallo compounds of metals, minerals, vitamins and amino acids that are showing excellent results on terminal patients and many others.
The poly-MVA is said to help in treating cancer as it protects the DNA and the RNA from harmful compounds that may alter the DNA composition of the cells leading formation of cancerous cells. It is rich in antioxidants and anti-tumor properties making it an effective alternative to cancer treatment that is free from all the side effects that is always the case with conventional treatment. By enhancing aerobic Cellular metabolism, Poly-MVA potentiates other therapies, attenuates side effects and enhances a patient’s quality of lifeAdditionally, many practitioners in the US and abroad continue to see significant successes integrating Poly-MVA into protocols for cancer, degenerative disease, and other health challenges.
What is PolyMVA
LAMC/Poly-MVA is a unique compound created through an innovative process whereby the mineral palladium is bound to alpha lipoic acid and Vitamin B1 (thiamine). When alpha lipoic acid, a unique and powerful antioxidant with multiple health benefits, is connected to an electrically charged mineral (palladium) and joined with thiamin (B1), the resulting complex is both water and fat soluble, dramatically increasing the entire body’s absorption of Poly-MVA at the cellular level.
With Vitamins B1, B2 and B12, specific trace minerals and amino acids, this unique complex and formulation create an amazing synergy, action, and function. It is designed to provide energy for the body’s systems as well as protect cells from oxidation through its proprietary and patented formulation. Poly-MVA was formulated by Dr. Merrill Garnett, who has conducted research on the actions of DNA within normal and abnormal cells.
Multiple studies have shown Poly-MVA’s effectiveness in many different cell lines, with cellular support occurring in normal cells. The benefit from the increase in oxygen and ATP is support for normal cellular function in other cells. The alpha lipoic acid, B-1, and mineral are irreversibly bound together, resulting in a molecule that is both fat and water soluble (so it travels to all parts of the body) and significantly more effective than any individual ingredient.
Poly-MVA has undergone extensive use and testing both orally and intravenously IV in various support roles of cancer, other degenerative diseases and as a daily preventative tonic, with a safety record of almost 20 years.
High Dose Vitamin C IV Therapy (HDC)
Vitamin C is a nutrient found in food and nutritional supplements. To achieve high blood levels, it is necessary to infuse vitamin C through an IV. High-dose vitamin C has been studied as a treatment for patients with cancer since the 1970s. Laboratory studies have shown that high doses of vitamin C may slow the growth and spread of prostate, pancreatic, liver, colon, and other types of cancer cells. The data show that ascorbic acid selectively kills cancer but not normal cells, using concentrations that could only be achieved by i.v. administration and conditions that reflect potential clinical use. In the Forsyth studies, HDC was combined with PolyMVA for maximum effectiveness.
Proactive Wellness Poly-MVA w/High Dose C Protocol (4 weeks)
The Proactive Wellness Poly-MVA with HDC protocol provides patients with a strengthened immune system, offset to some side effects of chemotherapy, cancer-fighting nutrients and antioxidant and cellular protection benefits. In the literature, the best outcomes were when using this protocol combined with chemotherapy administered in smaller doses more frequently than the conventional approach which is large doses infrequently. This aspect should be discussed with your oncologist.
Outcomes:
- From 2004-2006 Dr. James Forsythe studied 225 stage IV cancer patients, (multiple origins). Treatment with Poly-MVA or Poly-MVA + chemotherapy provided a 6-year Overall Survival rate of 32%, while the average 5-year survival rate is 2.1% in all stage IV cancers, as reported in the Clinical Journal of Oncology.
- Outcomes: Six year study from 2010 – 2016, Dr. James Forsythe reported a 70% survival rate across 1000 patients having various cancers.